Sugi Predict

Sugi Predict / Compounds / SCHEMBL492695

SCHEMBL492695

SCHEMBL492695

O=C(O)c1n[nH]c2ccc(OCc3ccccc3)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 1/20 0.60
▸ TTK P33981 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.54
▸ HPGD P15428 2/20 0.54
▸ PRKAG1 P54619 1/20 0.54
▸ PRKAA1 Q13131 1/20 0.54
▸ PRKAB1 Q9Y478 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ SRD5A2 P31213 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ MEN1 O00255 1/20 0.52
▸ HSP90AA1 P07900 1/20 0.52
▸ HSP90AB1 P08238 1/20 0.52
▸ LTA4H P09960 1/20 0.52
▸ PLA2G2A P14555 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ GSK3B P49841 1/20 0.51
▸ MAOA P21397 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8877124 0.90 TTK (0.55) HAO1TTKALDH1A1HPGDKDM4E
SCHEMBL12479877 0.90 MAOB (0.53) HAO1TTKALDH1A1HPGDKDM4E
SCHEMBL492399 0.90 ALDH1A1 (0.56) HAO1TTKALDH1A1HPGDPRKAG1
SCHEMBL17782603 0.86 TTK (0.49) HAO1TTKALDH1A1HPGDKDM4E
SCHEMBL492124 0.86 GABRA1 (0.63) TTKALDH1A1HPGDKDM4EMEN1
SCHEMBL6600100 0.85 GABRA1 (0.61) HAO1TTKALDH1A1HPGDKDM4E
SCHEMBL12480296 0.84 GSK3B (0.49) TTKALDH1A1HPGDPRKAG1PRKAA1
SCHEMBL627903 0.83 TTK (0.59) TTKKDM4ELTA4HPLA2G2AMAOA
SCHEMBL5988579 0.82 TTK (0.53) TTKALDH1A1HPGDKDM4ECYP1A2
Tert-Butyl Formate SCHEMBL28002279 0.81 GSK3B (0.46) HAO1TTKALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867227-B1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2018-11-21 — — EP disclosed
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
EP-2867225-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-08-09 — — EP disclosed
EP-2867229-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-07-26 — — EP disclosed
EP-2867224-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-07-26 — — EP disclosed
EP-2867224-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-07-26 — — EP disclosed
EP-2867229-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-07-26 — — EP disclosed
US-9487483-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2016-11-08 — — US disclosed
US-9487483-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2016-11-08 — — US disclosed
EP-1735306-A2 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF Memory Pharmaceuticals Corporation (US) 2006-12-27 — — EP disclosed
US-20050234095-A1 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION 2005-10-20 — — US disclosed
WO-2005092890-A2 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2005-10-06 — — WO disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 — — CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed
EP-0708105-B1 5-HT4 receptor agonists NISSHIN FLOUR MILLING CO (JP) 1998-12-23 — — EP disclosed
US-5684003-A GASTROINTESTINAL DISORDERS OR ANTIULCER AGENTS NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-11-04 — — US disclosed
EP-0708105-A1 5-HT4 receptor agonists NISSHIN FLOUR MILLING CO., LTD. (JP) 1996-04-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HAO1 3634/4885TTK 215/4885ALDH1A1 2583/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HAO1 3275/4885TTK 223/4885ALDH1A1 2459/4885
US-20050234095-A1 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof CHRNA7, CHRNA5, CHRNA3 HAO1 1324/4885TTK 3080/4885ALDH1A1 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.